Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-DOPS for Norepinephrine Replenishment in CIPA
NCT02624310Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Jan 2016
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of droxidopa in congenital insensitivity to pain with anhidrosis (CIPA), sponsored by NYU Langone Health. Planned start Jan 2016; status: withdrawn.
02
Drugs
droxidopa
03
Conditions
congenital insensitivity to pain with anhidrosis (CIPA)
Beyond the preview
Go deeper on NCT02624310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624310.